Miguel Zugman, Postdoctoral Research Fellow at City of Hope, shared a post on X:
“In the same week our letter to the editor on the SUNNIFORECAST trial’s control arm was published in Annals Oncology.
I happened to be in the same ESMO session as the authors – where they presented additional data on PD-L1 CPS and de-differentiated chromophobe RCC.”
You can also read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
ESMO 2025 Day 4 Highlights Not to Miss
ESMO 2025 Day 5 Highlights Not to Miss
